Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,190.18 -9.51 -0.30%
FTSE 100 6,671.81 -9.95 -0.15%
DAX 9,570.65 -29.44 -0.31%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Rosetta Genomics to Appoint Dr. Yitzhak Peterburg to its Board of Directors



 Rosetta Genomics to Appoint Dr. Yitzhak Peterburg to its Board of Directors

Former CEO of Clalit Health Services Brings Deep Healthcare Industry
Experience

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Nov. 8, 2012

PHILADELPHIA and REHOVOT, Israel, Nov. 8, 2012 /PRNewswire/ -- Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced summoning of a
shareholders meeting for the purpose of approving the appointment of Yitzhak
Peterburg, M.D., Dr.P.H., MSc. (age 61) to its Board of Directors.  Upon
approval of this addition by the Company's shareholders, the Company's Board
will consist of seven members.

Dr. Peterburg is a well-regarded pharmaceutical executive and entrepreneur
with deep healthcare industry experience.  He has served  on the Board of TEVA
Pharmaceuticals from 2009-2010 and   from 2010-2011 served as its Senior Vice
President, Head of Global Branded Products, with responsibility for branded
products, R&D, business development and in-licensing, after which, he returned
to his current Board position at TEVA.  

From 1990-2002 Dr. Peterburg was with Clalit Health Services, a
non-governmental, not-for-profit organization that provides comprehensive
health services to more than 55% of the Israeli population; Clalit Health
Services has an annual budget exceeding $3.5 billion and more than 45,000
employees.  From 1997 to 2002 he served as General Manager (CEO) for Clalit
Health Services and from 1990 to 1997 he held a series of senior executive
positions including Head, Health Policy Division and Chief Information
Officer, Medical Division.  Among his many positions at Clalit, from
1995-1997, Dr. Peterburg served as CEO of Soroka University Medical Center,
Beer-Sheba, Israel, one of the biggest university hospitals in Israel.

Following his tenure at Clalit, Dr. Peterburg was President and CEO of
Cellcom, one of Israel's leading cellular companies, which provides advanced
voice and data services to 2.5 million customers, where he managed a $ 1.4
billion annual budget and oversaw 4,000 employees.

"Dr. Peterburg is a tremendous addition to our Board of Directors," said
Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. 
"His extensive experience with branded pharmaceutical products combined with
his years of healthcare economics and healthcare policy experience as General
Manager of Clalit, position him as a valued adviser to guide the development
of Rosetta Genomics into a leader in molecular diagnostics and personalized
medicine."

Dr. Peterburg received his M.D. degree from Hadassah Medical School in
Jerusalem and is board-certified in Pediatrics and Health Services
Management.  He holds a Dr.P.H. in Health Administration from Columbia
University and an MSc degree in Information Systems from the London School of
Economics. Dr. Peterburg is a Professor in the School of Business, Ben-Gurion
University, Beer-Sheba.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure.  miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma.  miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics.  Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to Dr.
Peterburg's abilities to help guide the development of Rosetta into a leader
in molecular diagnostics and personalized medicine and Rosetta's
capitalization of its microRNA platform constitute forward-looking statements
for the purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995.  Actual results may differ materially from
those indicated by these forward-looking statements as a result of various
important factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta's Annual Report on Form 20-F for the year ended
December 31, 2011 as filed with the SEC.  In addition, any forward-looking
statements represent Rosetta's views only as of the date of this release and
should not be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any forward-looking
statements unless required by law.

Company Contact:                                           Investor Contacts:
Rosetta Genomics                                           LHA
Ken Berlin, President & CEO                                Anne Marie Fields
(215) 382-9000, ext. 326                                   (212) 838-3777
investors@rosettagenomics.com                              afields@lhai.com
                                                           or
                                                           Bruce Voss
                                                           (310) 691-7100
                                                           bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement